Atlas Trials

Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

Clinical trial NCT01940848 · COMPLETED

Trial details

NCT number
NCT01940848
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Irritable Bowel Syndrome
Start date
2013-10-11
Primary completion
2017-10-25
Enrollment
243

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.